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Curcumin, the major constituent of Curcuma longa L. (Zingiberaceae family) or turmeric, commonly used for cooking in Asian
cuisine, is known to possess a broad range of pharmacological properties at relatively nontoxic doses. Curcumin is found to be
effective against Staphylococcus aureus (S. aureus). As demonstrated by in vitro experiment, curcumin exerts even more potent
effects when used in combination with various other antibacterial agents. Hence, curcumin which is a natural product derived
from plant is believed to have profound medicinal benefits and could be potentially developed into a naturally derived antibiotic in
the future. However, there are several noteworthy challenges in the development of curcumin as a medicine. S. aureus infections,
particularly those caused by the multidrug-resistant strains, have emerged as a global health issue and urgent action is needed.This
review focuses on the antibacterial activities of curcumin against both methicillin-sensitive S. aureus (MSSA) and methicillin-
resistant S. aureus (MRSA). We also attempt to highlight the potential challenges in the effort of developing curcumin into a
therapeutic antibacterial agent.
1. Introduction
Curcumin or diferuloylmethane is the major phytochemical
of Curcuma longa L. (Zingiberaceae family), which is com-
monly known as turmeric. Curcumin is the polyphenolic
compound that gives the yellow colour of the herb. Turmeric
is mainly cultivated in tropical and subtropical regions and is
mainly produced by India. Traditionally, it has been used to
flavour food, dye cloths, and treat various human ailments [1].
Curcumin is extracted from turmeric by solvent extraction
(preferably with ethanol) through various methods (e.g.,
Soxhlet, ultrasonic, microwave, and supercritical carbon dio-
xide) followed by purification via column chromatography
[2, 3]. Ever since the identification of curcumin as the main
constituent of turmeric, multiple pharmacological activi-
ties of curcumin that include antimicrobial, antidiabetic,
anti-inflammatory, anticancer, and antioxidant have been
reported [4–6]. More excitingly, when combined with other
drugs, curcumin has been found to enhance the effects of
antibacterial [7–9], antifungal [10, 11], anticancer [12, 13], and
antioxidant [14, 15] activities.
Curcumin usually exhibits low to no toxicity at the active
doses. A systematic review from theMEDLINE computerized
database (1966 to 2002) has shown that curcumin is safe when
consumed up to 8 g each day consecutively for 3 months in a
phase I human trial that involved 25 subjects [16]. Similarly,
the dose of 8 g per day was safe when used in combination
with gemcitabine that showed marked therapeutic effects in
pancreatic cancer patients [17, 18]. Interestingly, curcumin
is also able to reverse the Aflatoxin B1-induced toxicity and
iron-overloaded liver toxicity in rats [19–21]. Despite being
extensively studied, the exact mechanism(s) of curcumin’s
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multiple biological and pharmacological activities remains
to be explored. Based on the available literature, there are
two hypotheses describing the poly-pharmacological effects
of curcumin. First, curcumin is known to act on multiple
targets [4, 5, 22–24], hence having diverse roles in regulating
various cellular processes. Secondly, products resulting from
the curcumin degradation have been shown to be highly
diverse depending on the chemical or biochemical reactions
involved [25–27]. Most of these products are stable and
function differently that may lead to the multiple effects.
The most studied activity of the curcumin in the past 10
years is the anticancer effects [28]. However, the first paper
describing the biological action of curcumin was its antibac-
terial activity against various bacteria: S. aureus, Trichophy-
ton gypseum, Salmonella paratyphi, and Mycobacterium
tuberculosis [29]. To date, studies on the antibacterial activity
of curcumin that indicate inhibition properties of a wide
range of bacteria are increasingly documented [6, 23, 30].
Recent publications have also reported that curcumin is
active against a plethora of drug-resistant bacterial strains
[8, 9, 31, 32]. S. aureus infection is a major problem in many
developing countries, especially in hospitals where theMRSA
spreading is difficult to control [33]. Over the years, themulti-
drug-resistant S. aureus infection has increased the global
morbidity andmortality [34, 35].Due to the difficulty in treat-
ing the infection, it has consequently imposed an elevating
burden on healthcare resources [36–38]. Cumulative findings
in recent years have shown that curcumin is active against
both MSSA and MRSA [8, 9, 30, 32, 39, 40]. In view of the
need for a more efficacious and safe therapeutic modality
towards the drug-resistant S. aureus, we discuss the reported
antibacterial activities of curcumin against S. aureus and
its potentials and limitations to be developed into a potent
antibiotic.
2. Curcumin-Mediated Inhibition of S. aureus
Curcumin inhibits the growth of both Gram-positive and
Gram-negative bacteria [6, 23, 30]. S. aureus is one of the
Gram-positive strains that is susceptible to curcumin-media-
ted inhibition. S. aureus is a pathogen that causes various
infections including infective endocarditis (IE), bacteremia,
skin and soft tissue, osteoarticular, and pleuropulmonary
infections [33]. Over the years, S. aureus has evolved and
developed multiple strategies to evade human immune sys-
tem and to resist antibiotics treatment. This has given rise
to the evolution of MRSA, and the emergence of healthcare-
associated (HA) and community-associated (CA) MRSA has
caused amajor problem to the human society [45, 46]. In this
section, we discuss the past and current works that show the
curcumin-mediated killings of MSSA and MRSA (summa-
rized in Table 1).
Mun et al. [9] showed that the minimal inhibitory conc-
entrations (MICs) of curcumin against 10 strains of S. aureus
(including 2 ATCC MSSA and MRSA standard strains, 4
MRSA clinical isolates, and 4 MRSA from culture collection)
ranged from 125 to 250 𝜇g/mL while a study by Wang et al.
[40] showed the MIC of 256𝜇g/mL against MSSA. Using a
broth microdilution assay, our group [8] also showed that
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Figure 1: Chemical structures of antibacterial curcumin analogues
against S. aureus. Upper panel shows the structure of curcumin-1
[30, 41] while the lower panel shows the metal complexes of cur-
cumin, indium curcumin [42, 43]. The chemical structures above
were drawn using a free online tool, ChemWriter (http://chemwriter
.com/).
250 𝜇g/mL curcumin was required to kill the two ATCC
MSSA (#25923) and MRSA (#43300) strains. However,
another study demonstrated that theMICs against the ATCC
standard MSSA and MRSA were 219 and 217 𝜇g/mL, respec-
tively, that are slightly lower than the former study [47].
Recently, Kali et al. [48] showed the mean curcumin MIC
of 126.9 𝜇g/mL against 15 Gram-positive bacterial isolates
including thirteen S. aureus and two Enterococcus faecalis.
Nonetheless, this study is not used for comparison in Table 1
because the obtained MIC might not be representative for
curcumin’s effect against S. aureus as the study was carried
out in combination with Enterococcus faecalis.
A more potent inhibition was achieved when curcumin-
1 (CUR-1), a major component of commercial preparations
of curcumin (purity > 98%), was used against S. aureus. The
chemical structure of curcumin-1 is shown in Figure 1. Tyagi
et al. [30] showed that the curcumin-1 was active against
MSSA at concentration of as low as 25𝜇M (equivalent to
9.21 𝜇g/mL), as it killed 50% of the bacteria after 2 hr incuba-
tion. The activity was time- and dose-dependent, and 100%
killing was achieved at 50𝜇M (equivalent to 18.42𝜇g/mL)
after 2 hr exposure [30]. In contrast, Sasidharan et al. [41]
showed that the same compound had a MIC of 250𝜇g/mL
against S. aureus, which is comparable to the native cur-
cumin [8, 9]. In an in vivo mouse model, administration of
100mg/kg curcumin was shown to protect the mice infected
with both MSSA and MRSA from pneumonia by targeting
the 𝛼-hemolysin (HIa) protein of S. aureus [40]. In summary,
the curcumin MICs against S. aureus ranged from 18.42 to
256𝜇g/mL (refer to Table 1). The variation could be due to
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Table 1: Antibacterial activity of curcumin against S. aureus.
Compound (solvent) MIC (𝜇g/mL) S. aureus strain Test method Reference
Curcumin (DMSO) 187.5 MSSA (ATCC 25923) Broth macrodilution [42]
Indium curcumin (DMSO) 93.8
Curcumin (DMSO) 125–250
MSSA (ATCC 25923)
MRSA (ATCC 33591)
MRSA (4 Clinical isolates)
MRSA (4 from CCARM)#
Broth microdilution [9]
Curcumin-1 (DMSO) 250 MSSA (MTCC 902)∗ Broth microdilution [41]
Curcumin (DMF) 250
MSSA (ATCC 25923)
MRSA (ATCC 43300)
MSSA (1 Clinical isolates)
MSSA (10 Env. isolates)
Broth microdilution [8]
Curcumin-1 (DMSO) 18.42 MSSA (ATCC 29213) Colony counting method [30]
Curcumin (ethanol) 219 MSSA (ATCC 29213) Broth macrodilution [47]
217 MRSA (ATCC 43300)
Curcumin (ethanol) 125 MSSA (ATCC 25923) Broth macrodilution [49]
Curcumin (DMSO) 256 MSSA (USA 300)MSSA (8325-4) Broth microdilution [40]
#CCARM: culture collection of antimicrobial resistant microbes.
∗Purchased fromMicrobial Type Culture Collection Centre (MTCC), IMTECH, Chandigarh, India.
Env.: environmental.
(i) strain difference (i.e., MRSA versus MSSA); (ii) source of
bacterial strains (i.e., ATCC standard strains versus clinical
isolates); (iii) type of antibacterial assay (i.e., disk diffusion
versus brothmicrodilution); and (iv) type of curcumin and its
solvent (i.e., commercial compound versus in-house purified
compound). Overall, the cumulative findings showed that
there is no difference of MICs against MSSA and MRSA,
suggesting that the sensitivity towards curcumin treatment
is not altered by the multidrug resistance machinery in S.
aureus.
There have been several explanations on how curcumin
acts and kills the bacteria which are illustrated in Figure 2.
Rai et al. [44] have demonstrated that curcumin interacts
with FtsZ (prokaryotic homologue of eukaryotic cytoskeletal
protein tubulin) in vitro and inhibits the assembly of FtsZ
protofilaments in Bacillus subtilis 168. Although it has not
been examined directly on S. aureus, it is believed that inhibit-
ing the assembly dynamics of FtsZ is one of the main mech-
anisms of curcumin in inhibiting bacterial cell proliferation.
FtsZ is also believed to be a novel target for the development
of antibacterial drugs against S. aureus. [63, 64]. Mun et al.
[32] showed that the antibacterial action of curcumin against
both MSSA and MRSA was markedly enhanced when used
in combination with ATPase inhibitors and mild detergents
that compromise ATP-binding cassette (ABC) transporters
and cytoplasmic membrane integrity, respectively. The same
study has also shown that curcumin binds to peptidoglycan
(PGN), and the increasing concentrations of PGN block the
curcumin antibacterial activity. Tyagi et al. [30] also showed
that curcumin-1 inhibited S. aureus growth by perturbing
the bacterial membrane integrity. In this study, the bacterial
membrane of S. aureus was examined using two fluores-
cent probes: propidium iodide and calcein. The membrane
leakage upon exposure to curcumin was also evaluated by
fluorescence and scanning electron microscopies. Although
existing evidence suggests that curcumin inhibits S. aureus
mainly by damaging the bacterial membrane, further inves-
tigation is required to identify additional bacterial target
proteins besides FtsZ and PGN. This is important not only
to enhance the understanding of the curcumin interaction
with its target proteins, but also to further improve the
activity of curcumin against S. aureus, particularly theMRSA
strains. Similar studies should also be performed on the
curcumin derivatives such as curcumin-1 (curcumin with
highest purity >98%) and indium curcumin (metal complex
with curcumin) which have shown more potent antibacterial
effects than the native curcumin. The chemical structures of
curcumin-1 and indium curcumin are shown in Figure 1.
3. Synergism of Curcumin with
Antibiotics against S. aureus
In addition to showing potent antibacterial activity when
used alone, curcumin also exerts marked activity against S.
aureus when used at subinhibitory dose in combination with
various other antibiotics [8, 9, 31, 32].These findings are inter-
esting since curcumin is naturally derived from turmeric,
which is one of the major ingredients of Asian cuisine [1,
23]. Of note, crude turmeric extracts have previously shown
marked antibacterial activities against S. aureus [6, 65, 66].
This section discusses the synergistic antibacterial activity
of curcumin with antibiotics against MSSA and MRSA.
Table 2 summarizes studies that demonstrated the synergism
of antibiotics-curcumin. In this table, we include the infor-
mation of curcumin type, solvent, and concentration, type of
bacteria-killing assay, and S. aureus strains for comparison.
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Figure 2: The potential mechanisms underlying the antibacterial effect of curcumin against S. aureus. Circle-shaped arrow indicates
binding whereas blocked arrow represents inhibition. (a) Curcumin may bind into FtsZ proteins, thereby inhibiting the assembly of FtsZ
protofilaments. This, in turn, suppresses the formation of Z-ring leading to inhibition of cytokinesis and bacterial proliferation [44]. (b) In
the case of MRSA, curcumin could inhibit the mecA gene transcription, causing reduced expression of PBP2𝛼 proteins. As a result, MRSA
can be sensitized towards the antibacterial action of 𝛽-lactam antibiotics such as Penicillin and Methicillin [32]. (c) The binding between
curcumin and peptidoglycan on S. aureus cell wall could trigger damage on the cell wall and membrane, leading to cell lysis of S. aureus
[30, 32].
Table 2: Synergism of curcumin against S. aureus.
Compound (solvent) Subinhibitoryconcentration Antibiotics S. aureus strain Test method Reference
Curcumin (not
reported) 500 𝜇g/disc
Cefixime
Cephotaxime
Vancomycin
Tetracycline
MSSA (1 clinical isolate) Disk diffusion [31]
Curcumin (DMSO)
Checkerboard
(various serial
dilutions)
Oxacillin
Ampicillin
Ciprofloxacin
Norfloxacin
MSSA (ATCC 25923)
MRSA (ATCC 33591)
MRSA (1 clinical isolate)
Broth microdilution [9]
Curcumin-1 (DMSO)
Checkerboard
(various serial
dilutions)
Cefaclor
Cefodizime
Cefotaxime
MSSA (MTCC 902)∗ Broth microdilution [41]
Curcumin (DMF) 25𝜇g/mL
Gentamicin
Amikacin
Ciprofloxacin
MSSA (ATCC 25923)
MRSA (ATCC 43300)
MSSA (1 clinical isolate)
MSSA (10 environ. isolates)
Disk diffusion &
broth microdilution [8]
Curcumin (DMSO) 32 𝜇g/mL
Penicillin
Erythromycin
Ciprofloxacin
MSSA (ATCC 25923)
MSSA (13 clinical isolates) Disk diffusion [48]
∗Purchased fromMicrobial Type Culture Collection Centre (MTCC), IMTECH, Chandigarh, India.
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The first study that reported the synergism of curcumin
against S. aureus was seven years ago by Moghaddam et al.
[31]. Using a disk diffusion method, Moghaddam et al. [31]
showed that 500𝜇g/disc of curcumin exerted synergistic
antibacterial effect on the MSSA when used in combination
with four antibiotics. Combinationwith cefotaxime, cefixime,
tetracycline, and vancomycin resulted in increase of inhibi-
tion zone of 52.6, 24.9, 26.5, and 24.4%, respectively.This was
then followed by Mun et al. [9] study in 2013 that showed
curcumin’s synergismwithOxacillin, Ampicillin, Ciprofloxa-
cin, and Norfloxacin against the MRSA.This study employed
checkerboard broth microdilution assay method to deter-
mine the synergistic activity. This method allows more stan-
dardised testing and is less laborious and suitable for studies
with multiple concentrations of test compounds [67]. Other
studies also showed the synergistic antibacterial effect of cur-
cumin against both MSSA and MRSA when used in combi-
nation with antibiotics such as Cefaclor, Cefodizime, Cefo-
taxime, Gentamicin, Amikacin, Penicillin, and Erythromycin
(refer to Table 2). Based on reported findings, the curcumin
synergism in combination with antibiotics appears to be rela-
tively nonspecific. Antibiotics classes that have shown syn-
ergism with curcumin include 𝛽-lactams, Cephalosporins,
Aminoglycosides, Glycopeptides, Tetracyclines, and Fluoro-
quinolones. This might due to the multitargeting action of
curcumin or their undetermined breakdown products as
pointed out in the previous section. More studies are needed
to evaluate the mechanism of curcumin synergism based on
the different classes of antibiotics. In addition to antibacterial
action, curcumin also reverses the drug resistance when used
in combinationwith other anticancer agents such as cisplatin,
5-fluorouracil, oxaliplatin, and doxorubicin in multiple types
of cancer cells including breast [68], colon [69], head and
neck [70], and ovary [71]. The curcumin may have acted on
the target or pathway related to the development of drug
resistance, hence restoring the killing effect of the drugs [72,
73]. This may be one of the mechanisms on how curcumin
enhances the effect of antibacterial drugs, especially when
they are targeting S. aureus-infected human cells.
In recent years, MRSA infection has emerged as a serious
infection due to its multidrug resistance (MDR) especially
in the hospital setting [74]. The MRSA infection may spread
rapidly especially when the disease is not well controlled.
Curcumin exhibits potent activity against MRSA, not only
when used alone, but also in combination with other antibi-
otics. In an effort to understand the curcumin’s anti-MRSA
effect, Mun et al. [32] showed that the Tris and Triton X-100
inhibited the bacterial growth to 63% and 59%, respectively,
when used together with curcumin. This suggests that bacte-
rial membrane permeability is partly responsible in regulat-
ing the antibacterial efficacy of curcumin against MRSA.The
same group has also shown that ATPase inhibitors (DCCD
and NaN
3
) which block the ATP-binding cassette (ABC)
enhanced the MRSA killing when used together with cur-
cumin. The importance of membrane permeability/integrity
in curcumin effect was also confirmed when the increase of
peptidoglycan (PGN) concentration successively blocked the
curcumin antibacterial activity [32]. These findings suggest
that any drug or inhibitor that primarily acts on the bacterial
membrane has higher chance of showing enhanced activity
when used together with curcumin. It is also noteworthy that
the expression of Penicillin-binding protein 2𝛼 (PBP2𝛼), a
protein responsible in conferring resistance towards𝛽-lactam
antibiotics, was downregulated in MRSA upon curcumin
treatment [32]. This protein which is encoded by MecA, a
nonnative gene in MRSA has significantly reduced affinity
for 𝛽-lactam antibiotics such as Methicillin and Penicillin.
Cell-wall biosynthesis, the target of 𝛽-lactam, could therefore
carry on in MRSA despite the presence of potent doses of
these antibiotics [75]. The detailed mode of action of cur-
cumin in inhibiting PBP2𝛼 expression in MRSA is not clear
at this juncture. It is plausible that curcumin may act on the
transcription of MecA gene, thereby blocking the expression
of PBP2𝛼 protein (Figure 2).
In addition to antibiotics, there are evidences showing
that curcumin augments the activity of other natural com-
pounds against MSSA and MRSA. Balan et al. [76] demon-
strated that combination of curcumin and whey proteins
markedly inhibited S. aureus growth in vitro. Sharma et al.
[77] have also previously reported the combination effect of
curcumin with several phytochemicals such as cinnamalde-
hyde, ellagic acid, and eugenol against Staphylococcus epider-
midis (S. epidermidis), which is closely related to S. aureus.
The combination activities as such against S. aureus remain
to be investigated. Indeed, there have been many studies
showing the potent antibacterial action of other natural com-
pounds against S. aureus such as thymoquinone [78], rhein
[79], emodin [80], silibinin [81], osthol [82], tannic acid [83],
and epigallocatechin gallate [84]. These findings warrant the
potential use of abovementioned compounds in combination
with curcumin against S. aureus.
4. The Challenges of Using Curcumin
as Antibiotic
Cumulative findings suggest that curcumin has broad-spec-
trum antibacterial activities and has synergistic effects with
other antibiotics in combination therapies in vitro [1, 6, 85].
Curcumin has also shown potent antibacterial action in the
mouse model [40]. Nonetheless, the curcumin antibacterial
activity has never been evaluated in clinical trials with an aim
of using it as a future antibiotic. In this section, we discuss
the underlying challenges from the clinical perspectives in
developing curcumin into a potential antibiotic.
While curcumin is known to possess the pharmacological
activities at relatively low doses, several studies have evi-
denced some cytotoxicity of curcumin [50–54, 86]. The first
study that demonstrated the curcumin toxicity was by Good-
pasture and Arrighi [50].They showed that turmeric resulted
in an induction of chromosome aberrations in tested cell
lines starting from 10 𝜇g/mL. Other studies have also shown
the toxic effects of curcumin mainly on the DNA damage
and chromosome aberrations [51–53]. While DNA alteration
is the starting point of carcinogenesis, the use of curcumin
under abovementioned conditionsmight be an issue. In other
words, curcumin treatment may cause cancers even though
the anticancer action of curcumin is well documented. In
1993, a study has concluded that turmeric oleoresin (turmeric
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extract containing 79–85% of curcumin) has carcinogenic
property in rats and mice [54]. Mice taking 0.2mg/kg body
weight of curcumin daily average were found to have carci-
nomas in their small intestines. Curcumin has also shown
to promote lung cancer in another study [55]. The tumour-
promoting activity of curcumin has been linked to the induc-
tion of reactive oxygen species (ROS) production such as
superoxide anion and hydrogen peroxide [87–89].
As curcumin is an active iron chelator, it may potentially
affect systemic iron metabolism especially those who have
suboptimal iron status [56]. Furthermore, curcumin has been
reported to block the enzymes that metabolize drugs such as
cytochromeP450s [57, 58].Thismay lead to the accumulation
of nonmetabolized drugs in blood and result in undesired
toxicity. In human, nonetheless, the side effects of curcumin
have been relatively mild. A human trial has shown that
curcumin ranging from 0.9 to 3.6 g per day up to 4 months
only caused some adverse effects that included nausea, diar-
rhea, and increased serum alkaline phosphatase and lactate
dehydrogenase [90]. In 2010, Balaji and Chempakam [91]
have predicted a few toxigenic and potent compounds from
turmeric using a cost-effective cheminformatics approach.
This method can be adopted to select the effective but non-
toxic curcumin or its derivatives for further biological studies.
However, the selected compound has to be evaluated in a
long-term study at its active dose against S. aureus in order to
confirm the safety of using curcumin as a potential antibiotic.
Curcumin is usually extracted from turmeric plant
mainly by solvent extraction followed by column-based
purification [2, 3]. Curcumin is sparingly soluble in water
(<0.1mg/mL) and is mainly dissolved in organic solvents
such as DMSO, DMF, or ethanol (Tables 1 and 2). This may
be the major concern when it is administered into human
system as human plasma is composed of 92% of water. The
water-insoluble nature may affect curcumin bioavailability
and hence affect its pharmacological potential [26, 27, 61].
To this end, several methods have been developed in recent
years to circumvent the poor solubility and stability of cur-
cumin, therebymaximizing its pharmacological or biological
actions. For example, it has been reported that the use of heat
could enhance the curcumin solubility [59, 60]. Kurien et al.
[59] have reported the improved water solubility of curcumin
from 0.6 to 7.4 𝜇g/mL, without displaying heat-mediated des-
truction of the chemical structure. Development of curcumin
bioconjugates has also shown to be an effective method of
enhancing the curcumin solubility. For instances, conjuga-
tion of curcumin with hyaluronic acid formed micelles in
aqueous phase at physiological pH and appeared to be non-
toxic [92]. Dey and Sreenivasan have also conjugated cur-
cumin with alginate, a natural polysaccharide product, in
order to increase its stability and bioavailability [93]. Other
macromolecules that could serve as carrier systems for cur-
cumin include beta-casein [94], chitosan/Tween 20 [95],
emulsomes [96], sodiumcaseinate [97], and albumin [98, 99].
The development of curcumin nanoformulations has been
extensively reviewed in light of its anticancer action [100–
102].While increasing number of curcumin nanoformulation
is being introduced into the therapeutic field, it is important
to ensure that the bioconjugates or nanoformulations do not
Table 3: Challenges of curcumin use in clinical setting.
Challenge References
Cytotoxicity
DNA damage and chromosome aberrations [50–53]
Carcinogenesis
Promote tumour formation in vivo [54, 55]
Iron chelation
Alter systemic iron metabolism [56]
Enzyme inhibition
Inhibit drug-metabolizing enzymes [57, 58]
Solubility
Hydrophobic nature does not support water
solubility [59, 60]
Bioavailability
Degradation by plasma protease and
nonspecific protein binding [26, 27, 61, 62]
diminish the antibacterial effects of curcumin at the expense
of improved bioavailability in order to develop them into
effective antibiotics in the future.
In addition to potential toxicity, poor solubility, and
low bioavailability, curcumin encounters multiple challenges
when it is administered either through oral or intravenous
route due to the nature of body system [26, 59, 61, 62]. A large
amount of curcumin may get degraded in the presence of
detoxifying and metabolic enzymes, or it may bind to the
circulatory proteins such as albumin which may potentially
reduce its activity. Contradictorily, there have been evidences
showing that degraded products from curcumin are respon-
sible of its pharmacological activities [26, 27]. Furthermore,
it has been shown that albumin-bound curcumin exerted
similar level of activity compared to the DMSO-dissolved
curcumin in serum [103]. Of note, the curcumin degradation
and binding with physiological proteins have not been evalu-
ated in light of the curcumin antibacterial action.Whether or
not these factorswould affect the activity of curcumin, further
investigations are required. Notably, development of the
curcumin bioconjugates, nanoformulations, or derivatives
could be the key to overcome the challengesmentioned above
(summarized in Table 3). The development of modified cur-
cumin has been recently reviewed [62, 100, 101].
5. Conclusion
Curcumin has shown potent antibacterial activity and other
pharmacological actions in the past 50 years. Curcumin has
been marketed globally as a health supplement mainly for its
antioxidant and anti-inflammatory properties. In addition,
it also has high potential to be developed into an antibiotic
against S. aureus and other bacterial strains in the future.
However, the challenges mentioned in the preceding sections
should be taken into consideration to open the door for the
development of more biologically active curcumin deriva-
tives. To the best of our understanding, this is the first review
that compares and summarizes the curcumin antibacterial
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activity against S. aureus. More investigation is required in
order to better understand the broad action of curcumin prior
to develop this compound or its derivatives into a potential
antibiotic.
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